DuoGenic StemCells corporation - 7607.TWO - Fundamentals

Feel free to try out our engine!Whenever you're ready, pick a plan!

Best Investments/trading ideas for the weekJoin our free webinar on September23,2026.

Insider Tracker is here!

Try it now Watch the presentation

‌
‌

‌

Let's get started...

‌

Breakdown	2021 12/31	2022 12/31	2023 12/31	2024 12/31	2025 12/31	TTM
REVENUE	2	7	14	12	21	21	📊
Revenue Growth (1Y)	--	+198.74%	+99.17%	-11.82%	+71.70%	-0.45%	📊
Revenue Growth (5Y)	--	--	--	--	+800.87%	+796.78%	📊
Revenue Growth (10Y)	--	--	--	--	--	--	📊
Cost of Revenue	7	7	9	8	5	7	📊
Cost of Revenue Growth (1Y)	--	+0.55%	+19.88%	-9.34%	-38.38%	+33.63%	📊
Cost of Revenue Growth (5Y)	--	--	--	--	-32.66%	-10.02%	📊
Cost of Revenue Growth (10Y)	--	--	--	--	--	--	📊
Gross Profit	-5	-0	5	4	16	14	📊
Gross Profit Growth (1Y)	--	+90.92%	+1183.85%	-16.25%	+284.96%	-11.02%	📊
Gross Profit Growth (5Y)	--	--	--	--	+417.36%	+382.38%	📊
Gross Profit Growth (10Y)	--	--	--	--	--	--	📊
Operating Expenses	18	33	5	65	42	48	📊
Operating Expenses Growth (1Y)	--	+81.49%	-85.14%	+1229.13%	-36.13%	+16.50%	📊
Operating Expenses Growth (5Y)	--	--	--	--	+128.95%	+166.71%	📊
Operating Expenses Growth (10Y)	--	--	--	--	--	--	📊
Sell General Administrative	8	19	35	41	26	33	📊
Research and Development	10	14	14	24	15	16	📊
Other Income Expenses	0	-0	0	0	-0	--	📊
EBITDA	-20	-28	-38	-54	-20	-29	📊
EBITDA Growth (1Y)	--	-40.72%	-33.76%	-41.90%	+63.50%	-45.85%	📊
EBITDA Growth (5Y)	--	--	--	--	+2.52%	-42.17%	📊
EBITDA Growth (10Y)	--	--	--	--	--	--	📊
Depreciation and Amortization	3	5	7	7	6	5	📊
Operating Income	-23	-33	-45	-61	-26	-34	📊
Operating Income Growth (1Y)	--	-44.41%	-34.31%	-35.93%	+57.72%	-33.35%	📊
Operating Income Growth (5Y)	--	--	--	--	-11.46%	-48.62%	📊
Operating Income Growth (10Y)	--	--	--	--	--	--	📊
Interest Expense	0	0	0	1	1	1	📊
Pre Tax Income	-23	-34	-45	-62	-26	-34	📊
Tax Provision	-1	0	0	-0	-0	--	📊
NET INCOME	-22	-34	-45	-62	-26	-34	📊
Net Income Growth (1Y)	--	-54.91%	-32.85%	-36.13%	+57.16%	-30.13%	📊
Net Income Growth (5Y)	--	--	--	--	-20.02%	-56.18%	📊
Net Income Growth (10Y)	--	--	--	--	--	--	📊
Basic EPS	-0.86	-1.18	-1.5	0	0	-1.02	📊
Diluted EPS	-0.86	-1.18	-1.5	0	0	-1.02	📊
Basic Average Shares	26	29	30	0	0	33	📊
Diluted Average Shares	26	29	30	0	0	33	📊

Breakdown	2021 12/31	2022 12/31	2023 12/31	2024 12/31	2025 12/31	TTM
REVENUE	2	7	14	12	21	21	📊
Revenue Growth (1Y)	--	+198.74%	+99.17%	-11.82%	+71.70%	-0.45%	📊
Revenue Growth (5Y)	--	--	--	--	+800.87%	+796.78%	📊
Revenue Growth (10Y)	--	--	--	--	--	--	📊
Cost of Revenue	7	7	9	8	5	7	📊
Cost of Revenue Growth (1Y)	--	+0.55%	+19.88%	-9.34%	-38.38%	+33.63%	📊
Cost of Revenue Growth (5Y)	--	--	--	--	-32.66%	-10.02%	📊
Cost of Revenue Growth (10Y)	--	--	--	--	--	--	📊
Gross Profit	-5	-0	5	4	16	14	📊
Gross Profit Growth (1Y)	--	+90.92%	+1183.85%	-16.25%	+284.96%	-11.02%	📊
Gross Profit Growth (5Y)	--	--	--	--	+417.36%	+382.38%	📊
Gross Profit Growth (10Y)	--	--	--	--	--	--	📊
Operating Expenses	18	33	5	65	42	48	📊
Operating Expenses Growth (1Y)	--	+81.49%	-85.14%	+1229.13%	-36.13%	+16.50%	📊
Operating Expenses Growth (5Y)	--	--	--	--	+128.95%	+166.71%	📊
Operating Expenses Growth (10Y)	--	--	--	--	--	--	📊
Sell General Administrative	8	19	35	41	26	33	📊
Research and Development	10	14	14	24	15	16	📊
Other Income Expenses	0	-0	0	0	-0	--	📊
EBITDA	-20	-28	-38	-54	-20	-29	📊
EBITDA Growth (1Y)	--	-40.72%	-33.76%	-41.90%	+63.50%	-45.85%	📊
EBITDA Growth (5Y)	--	--	--	--	+2.52%	-42.17%	📊
EBITDA Growth (10Y)	--	--	--	--	--	--	📊
Depreciation and Amortization	3	5	7	7	6	5	📊
Operating Income	-23	-33	-45	-61	-26	-34	📊
Operating Income Growth (1Y)	--	-44.41%	-34.31%	-35.93%	+57.72%	-33.35%	📊
Operating Income Growth (5Y)	--	--	--	--	-11.46%	-48.62%	📊
Operating Income Growth (10Y)	--	--	--	--	--	--	📊
Interest Expense	0	0	0	1	1	1	📊
Pre Tax Income	-23	-34	-45	-62	-26	-34	📊
Tax Provision	-1	0	0	-0	-0	--	📊
NET INCOME	-22	-34	-45	-62	-26	-34	📊
Net Income Growth (1Y)	--	-54.91%	-32.85%	-36.13%	+57.16%	-30.13%	📊
Net Income Growth (5Y)	--	--	--	--	-20.02%	-56.18%	📊
Net Income Growth (10Y)	--	--	--	--	--	--	📊
Basic EPS	-0.86	-1.18	-1.5	0	0	-1.02	📊
Diluted EPS	-0.86	-1.18	-1.5	0	0	-1.02	📊
Basic Average Shares	26	29	30	0	0	33	📊
Diluted Average Shares	26	29	30	0	0	33	📊

DuoGenic StemCells corporation - 7607.TWO - Fundamentals - Financial Statements

Ex-Dividend date	--
Payment date	--
Annual Dividend	--
Dividend Yield	--
Shareholders Yield	-7.92%
Next Earnings	--
Market cap	365.13M (TWD)
EPS (TTM)	-1.02 (TWD)
P/E (TTM)	-10.00 (TWD)
Last Close	10.20

Next Earnings	--
Market cap	365.13M (TWD)
EPS (TTM)	-1.02 (TWD)
P/E (TTM)	-10.00 (TWD)
Last Close	10.20 (TWD)

Ex-Dividend date	--
Payment date	--
Annual Dividend	--
Dividend Yield	--
Shareholders Yield	-7.92%
Next Earnings	--
Market cap	365.13M (TWD)
EPS (TTM)	-1.02 (TWD)
P/E (TTM)	-10.00 (TWD)
Last Close	10.20

Next Earnings	--
Market cap	365.13M (TWD)
EPS (TTM)	-1.02 (TWD)
P/E (TTM)	-10.00 (TWD)
Last Close	10.20 (TWD)